Journal
MEDICINE
Volume 100, Issue 13, Pages -Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MD.0000000000024567
Keywords
acute promyelocytic leukemia; arsenic trioxide; case report; myelofibrosis; retinoic acid
Categories
Funding
- National Natural Science Foundation of China [81971508, 81471589, 81273259]
Ask authors/readers for more resources
This case report highlighted the rarity of acute promyelocytic leukemia with myelofibrosis and emphasized the importance of evaluating and intervening in cases of myelofibrosis.
Rationale: Acute promyelocytic leukemia (APL) with myelofibrosis (MF) is rare, and only 14 cases have been reported in the literature to date. Patient concerns: A 42-year-old woman was admitted to the hospital with easy bruising and excessive bleeding. With the remission of the primary disease during treatment, the degree of fibrosis did not decrease, but worsened progressively. Diagnosis: The woman was diagnosed with acute promyelocytic leukemia with secondary myelofibrosis. Interventions: All-trans retinoic acid (ATRA) was discontinued after 6 months of complete remission of APL. Arsenic trioxide (ATO) was discontinued because of supraventricular tachycardia 9 months after complete remission of APL. Outcomes: After withdrawal of ATRA for 2 months, the degree of fibrosis was significantly alleviated, and after withdrawal of ATRA for 8 months and ATO for 5 months, bone marrow biopsy showed no reticular fiber deposition. Lessons: In this case report and review of an additional 14 cases of APL with MF, we highlighted the importance of the degree of MF to be evaluated by bone marrow biopsy at the time of bone marrow aspiration when APL is suspected. If MF is present, the type of MF should be determined in a timely manner, and appropriate intervention measures should be taken accordingly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available